Jose L. Blanco

Dr. Jose L. Blanco


Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 July 2022 in Eurosurveillance
Verified
Journal Article
Open access
APAida Peiró-Mestres
Aida Peiró-Mestres
IFIrene Fuertes
Irene Fuertes
DCDaniel Camprubí-Ferrer
Daniel Camprubí-Ferrer
MMMaría Ángeles Marcos
María Ángeles Marcos
AVAnna Vilella
Anna Vilella
OGon behalf of the Hospital Clinic de Barcelona Monkeypox Study Group
on behalf of the Hospital Clinic de Barcelona Monkeypox Study Group
A monkeypox (MPX) outbreak has expanded worldwide since May 2022. We tested 147 clinical samples collected at different time points from 12 patients by real-time PCR. MPX DNA was detected in saliva from all cases, sometimes with high viral loads. Other samples were frequently positive: rectal swab (11/12 cases), nasopharyngeal swab (10/12 cases), semen (7/9 cases), urine (9/12 cases) and faeces (8/12 cases). These results improve knowledge on virus shedding and the possible role of bodily fluids in disease transmission.

7 August 2020 in AIDS
Verified
Journal Article
Closed access
AIAlexy Inciarte
Alexy Inciarte
AGAna Gonzalez-Cordon
Ana Gonzalez-Cordon
JRJhon Rojas
Jhon Rojas
BTBerta Torres
Berta Torres
ELElisa de Lazzari
Elisa de Lazzari
JBJose L. Blanco
Jose L. Blanco
Background: It is unclear how characteristics, risk factors, and incidence of coronavirus disease 2019 (COVID-19) in people living with HIV (PLWH) differ from the general population. Methods: Prospective observational single-center cohort study of adult PLWH reporting symptoms of COVID-19. We assessed clinical characteristics, risk factors for COVID-19 diagnosis and severity, and standardized incidence rate ratio for COVID-19 cases in PLWH cohort and in Barcelona. Results: From 1 March 2020 to 10 May 2020, 53 out of 5683 (0.9% confidence interval 0.7–1.2%) PLWH were diagnosed with COVID-19. Median age was 44 years, CD4+ T cells were 618/μl and CD4+/CD8+ was 0.90. All but two individuals were virologically suppressed. Cough (87%) and fever (82%) were the most common symptoms. Twenty-six (49%) were admitted, six (14%) had severe disease, four (8%) required ICU admission, and two (4%) died. Several laboratory markers (lower O2 saturation and platelets, and higher leukocytes, creatinine, lactate dehydrogenase, C reactive protein, procalcitonin, and ferritin) were associated with COVID-19 severity. No HIV or antiretroviral-related factors were associated with COVID-19 diagnosis or severity. Standardized incidence rate ratios of confirmed or confirmed/probable COVID-19 in PLWH were 38% (95% confidence interval 27–52%, P < 0.0001) and 33% (95% confidence interval 21–50%, P < 0.0001), respectively relative to the general population. Conclusion: PLWH with COVID-19 did not differ from the rest of the HIV cohort. Clinical presentation, severity rate, and mortality were not dependent on any HIV-related or antiretroviral-related factor. COVID-19 standardized incidence rate was lower in PLWH than in the general population. These findings should be confirmed in larger multicenter cohort studies.

1 February 2007 in JAIDS Journal of Acquired Immune Deficiency Syndromes
Verified
Journal Article
Open access
MLMontserrat Laguno
Montserrat Laguno
MLMaría Larrousse
María Larrousse
JMJavier Murillas
Javier Murillas
JBJose L. Blanco
Jose L. Blanco
ALAgathe León
Agathe León
JMJosep Mallolas
Josep Mallolas
As a result of adverse events, a moderate rate of virologic response, and high costs associated with hepatitis C virus (HCV) therapy, finding early markers of sustained treatment response is a clinical priority. In the HCV-monoinfected population, a reduction >or=2 log in plasma HCV RNA at week 12 of therapy (early virologic response [EVR]) predicts a sustained virologic response (SVR). Few data are available in HIV/HCV-coinfected patients, however. A subanalysis of data from HIV/HCV-coinfected patients treated with pegylated interferon-alpha-2b (PEG, 100-150 mug/wk) or interferon-alpha-2b (IFN, 3 MIU 3 times per week) plus ribavirin (RBV, 800-1200 mg/d) was conducted in a randomized single-center clinical trial. The duration of treatment was 48 weeks (only 24 weeks for HCV genotype 2 or 3 with a baseline HCV RNA level <800,000 IU/mL). Ninety-five patients were randomized (43 assigned to IFN + RBV and 52 assigned to PEG + RBV). Eighty patients completed at least 12 weeks on therapy and were included in the EVR analysis. Thirty-five (43%) of them attained an SVR (56% and 30% of patients treated with PEG and IFN, respectively; P = 0.026). An EVR occurred in 55 (69%; 80% of PEG + RBV group and 56% of IFN + RBV group). Overall, 35 of 55 patients with an EVR were sustained responders, yielding a positive predictive value of 64% (70% in PEG + RBV arm and 55% in IFN + RBV arm). None of the patients who demonstrated an HCV RNA decline of <2 logs at week 12 reached an SVR (negative predictive value of 100%). Our results confirm the utility of an EVR to predict the chance of the lack of an SVR in HIV/HCV-coinfected patients, particularly those treated with PEG.

16 February 2023 in Ophthalmology
Verified
Journal Article
Closed access
MPMarta Pazos
Marta Pazos
JRJosep Riera
Josep Riera
AMAina Moll-Udina
Aina Moll-Udina
ACAlba Catala
Alba Catala
SNSofia Narvaez
Sofia Narvaez
JBJose L. Blanco
Jose L. Blanco

3 November 2023 in Microorganisms
Verified
Journal Article
Open access
PDF file
RMRaquel Martín-Iguacel
Raquel Martín-Iguacel
CPCarles Pericas
Carles Pericas
ABAndreu Bruguera
Andreu Bruguera
GRGemma Rosell
Gemma Rosell
EMErica Martínez
Erica Martínez
Josep Maria LlibreJosep Maria Llibre
Josep Maria Llibre
We investigated differences in mpox clinical outcomes in people with HIV (PWH) and without HIV (PWoH) and the impact of vaccination in Catalonia, Spain. We used surveillance data and the PISCIS HIV cohort. We included all confirmed mpox cases (May–December 2022). Of 2122 mpox cases, the majority had mild disease, 56% were Spanish, and 24% were from Latin America. A total of 40% were PWH, with a median CD4+T-cell of 715 cells/μL; 83% had HIV-RNA < 50 copies/mL; and 1.8% CD4+T-cell < 200 cells/μL. PWH had no increased risk for complications, except those with CD4+T-cell < 200 cells/μL. PWH with CD4+T-cell < 200 cells/μL were more likely to be from Latin America, had more generalized exanthema, and required hospitalization more frequently (p = 0.001). Diagnosis of other sexually transmitted infections (STIs) was common, both at mpox diagnosis (17%) and two years before (43%). Dose-sparing smallpox intradermal vaccination was accompanied by a sharp decrease in mpox incidence in both populations (p < 0.0001). In conclusion, unless immunosuppressed, PWH were not at increased risk of severe disease or hospitalization. Mpox is a marker of high-risk sexual behavior and was associated with high HIV and STI rates, supporting the need for screening in all mpox cases. Ethnicity disparities demonstrate the need for interventions to ensure equitable healthcare access. Dose-sparing smallpox vaccination retained effectiveness.

14 October 2005 in AIDS
Verified
Journal Article
Open access
ALAgathe León
Agathe León
JMJosep Mallolas
Josep Mallolas
EMEsteban Martinez
Esteban Martinez
ELElisa De Lazzari
Elisa De Lazzari
TPTomàs Pumarola
Tomàs Pumarola
JGJosep María Gatell
Josep María Gatell
We evaluated the virological outcome of tenofovir plus didanosine-based regimens in 67 HIV-suppressed patients. After a median follow-up of 26 months (IQR 10.5–40.5), 12 (18%) discontinued the therapy because of virological failure. At virological failure ‘de novo’ selected mutations were identified in 11 of the 12 failing patients, including the K65R mutation in seven patients. These results argue against the use of tenofovir–didanosine not only in naive patients, but also in previously suppressed patients.